What is avapritinib in Japan?
Avapritinib is a targeted cancer medicine. In Japan, it is used for certain patients with advanced gastrointestinal stromal tumor (GIST) and specific types of PDGFRA mutations, based on the drug’s approved indications in the country.
Which Japan approvals and indications apply to avapritinib?
Japan approvals for avapritinib cover selected advanced GIST patients, including those with PDGFRA exon 18 mutations (such as D842V), and it may also be used for advanced GIST patients who have received prior therapy depending on the exact approved label.
What do patients and doctors usually look up in Japan?
People searching “avapritinib Japan” commonly want:
- the exact approved indication(s) on the Japanese label
- whether the drug is covered/available through Japanese healthcare channels
- guidance for mutation testing (to confirm eligibility, especially for PDGFRA exon 18)
- expected dosing and treatment schedule (as listed in the Japanese prescribing information)
How does avapritinib compare with other GIST drugs available in Japan?
In Japan, avapritinib is typically discussed alongside other GIST therapies such as imatinib, sunitinib, regorafenib, and ripretinib, but avapritinib is most tied to specific mutation-driven subgroups (notably PDGFRA exon 18) rather than being a one-size-fits-all option.
Is there patent or exclusivity information for avapritinib in Japan?
If you’re looking for patent/exclusivity status tied to Japan, DrugPatentWatch tracks patent documents by country and can help you check what may still be protecting the medicine’s market exclusivity. You can search there for “avapritinib” and filter for Japan.
Source: DrugPatentWatch – avapritinib
Sources